In Brief: Kensey Nash
This article was originally published in The Gray Sheet
Kensey Nash: Commences an "early ambulation clinical trial" of its 8 French Angio-Seal device for sealing arterial punctures created during angiography and percutaneous transluminal coronary angioplasty procedures. The study will evaluate the ability of the device to reduce patients' time to ambulation following angioplasty and PTCA. American Home Products, Kensey Nash's partner in developing Angio-Seal, will jointly administer the study, which is expected to enroll 340 patients at eight U.S. centers. Results of the study would support a supplemental application to Kensey Nash's pending PMA for Angio-Seal. Kensey Nash says it is working to resolve issues related to an FDA premarket inspection of manufacturing facilities for Angio-Seal. The company received an approvable letter for the device in July 1995...
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.